Eli Lilly’s Zepbound outperforms Novo Nordisk’s Wegovy for weight loss in trial
(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such ...
Read moreDetailsTag: obesity drug
Investors seek answers on Novo Nordisk’s next-gen obesity drug CagriSema
By Maggie Fick and Robin Respaut LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information ...
Read moreDetails
